HeartSciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by HeartSciences Inc. on April 3, 2026, covering events occurring on April 1, 2026. The Company is an emerging growth company incorporated in Texas, with its principal executive offices in Southlake, Texas. Its common stock (HSCS) and warrants (HSCSW) trade on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial performance data.
Material Changes
- Departure of Key Officer: Mark Hilz, Chief Operating Officer, Corporate Secretary, and Board Member, passed away on April 1, 2026, at age 67 following an illness.
- Role Status: Mr. Hilz had served on the Board since 2013 and as COO/Corporate Secretary since March 2022.
- Operational Continuity: The Company does not anticipate hiring a replacement for the COO role in the foreseeable future.
Outlook, Management Commentary, and Risks
Management, led by President and CEO Andrew Simpson, stated that the Company does not anticipate any changes to its business, operations, or planned commercialization efforts due to Mr. Hilz's passing. Key milestones remain on track:
- The MyoVista Insights software platform has been launched.
- The MyoVista wavECG device submission for FDA 510(k) premarket clearance, originally submitted in December 2025, remains active.
Investor Verification Checklist
- Confirm the status of the MyoVista wavECG FDA 510(k) clearance process following the leadership change.
- Verify the interim arrangement for Corporate Secretary duties, given Mr. Hilz held that title.
- Monitor future filings for any updates on the Board of Directors composition or potential new appointments.